PBRM1 and urothelial carcinoma: However, multiple retrospective analyses report that the status of the PBRM1 mutation is not associated with the clinical benefit of various ICI in other solid tumor types, including non-small cell lung cancer, urothelial carcinoma, melanoma, or esophagogastric cancer, suggesting that the impact of loss of function of PBRM1 may depend on the type of tumor (38).